![]() |
|
|
Vol. 284, Issue 1, 43-50, 1998
Formulation R & D Laboratories (T.I., M.I, K.H., Y.T.) and
Discovery Research Laboratories II (K.M., T.M.), Shionogi & Co., Ltd.,
Fukushima-ku, Osaka 553, Japan
The mechanism of the hypocholesterolemic action of S-8921, methyl
1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-
6,7,8-trimethoxy-2-naphthoate, was examined in rats. In diet-induced
hypercholesterolemic rats, 2 weeks oral administration of S-8921 dose-
and time-dependently decreased plasma cholesterol level in the daily
dose range of 0.1to10 mg/kg. Results with the dual-isotope plasma ratio
method indicated that S-8921 inhibits cholesterol absorption from the intestine and enhances its elimination from the body. The in
situ loop method showed that S-8921 does not inhibit the
absorption of cholesterol from rat jejunum, clearly inhibits active
absorption of taurocholic acid (TCA) and glycocholic acid (GCA) from
rat ileum and does not inhibit passive absorption of cholic acid (CA) from the rat jejunum. In rat ileal brush-border membrane vesicles, S-8921 inhibited the sodium-dependent uptake of TCA in a
concentration-dependent manner with IC50 of 2.1 µM, not
the Na+-dependent D-glucose and
L-alanine uptake. These results suggest that S-8921 is a
potent, selective inhibitor of the Na+-dependent bile acid
transport system in the ileal mucosal cell brush-border membrane, and
this inhibition is the mechanism by which this drug decreases
intestinal bile acid reabsorption to result in a significant decrease
of plasma cholesterol.
This article has been cited by other articles:
![]() |
B. G. Bhat, S. R. Rapp, J. A. Beaudry, N. Napawan, D. N. Butteiger, K. A. Hall, C. L. Null, Y. Luo, and B. T. Keller Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435 J. Lipid Res., September 1, 2003; 44(9): 1614 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Galman, I. Arvidsson, B. Angelin, and M. Rudling Monitoring hepatic cholesterol 7{alpha}-hydroxylase activity by assay of the stable bile acid intermediate 7{alpha}-hydroxy-4-cholesten-3-one in peripheral blood J. Lipid Res., April 1, 2003; 44(4): 859 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Izzat, M. E. Deshazer, and D. S. Loose-Mitchell New Molecular Targets for Cholesterol-Lowering Therapy J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 315 - 320. [Abstract] [Full Text] |
||||
![]() |
J. Higaki, S. Hara, N. Takasu, K. Tonda, K. Miyata, T. Shike, K. Nagata, and T. Mizui Inhibition of Ileal Na+/Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits Arterioscler. Thromb. Vasc. Biol., August 1, 1998; 18(8): 1304 - 1311. [Abstract] [Full Text] [PDF] |
||||